Symbols / BCLI
BCLI Chart
About
Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 6.95M |
| Enterprise Value | 7.22M | Income | -10.85M | Sales | — |
| Book/sh | -0.70 | Cash/sh | 5000.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 23 | IPO | — |
| P/E | — | Forward P/E | -0.59 | PEG | — |
| P/S | — | P/B | -0.90 | P/C | — |
| EV/EBITDA | -0.68 | EV/Sales | — | Quick Ratio | 0.01 |
| Current Ratio | 0.06 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.42 | EPS next Y | -1.07 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-31 | ROA | -4.00% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 11.03M |
| Shs Float | 10.06M | Short Float | 6.46% | Short Ratio | 1.27 |
| Short Interest | — | 52W High | 1.92 | 52W Low | 0.46 |
| Beta | 0.70 | Avg Volume | 23.91K | Volume | 16.20K |
| Target Price | — | Recom | Hold | Prev Close | $0.61 |
| Price | $0.63 | Change | 3.26% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.63
Latest analyst target
3. DCF / Fair value
$-5.63
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.63
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-07-11 | up | Maxim Group | Hold → Buy | $2 |
| 2023-09-28 | down | Maxim Group | Buy → Hold | — |
| 2023-03-31 | main | Maxim Group | — → Buy | $10 |
| 2021-02-05 | up | Maxim Group | Hold → Buy | — |
| 2018-05-15 | init | HC Wainwright & Co. | — → Buy | $11 |
| 2017-08-17 | main | Maxim Group | — → Buy | $9 |
- Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market - PR Newswire Fri, 20 Feb 2026 11
- Brainstorm Cell Therapeutics Announces New Private Placement Financing - The Globe and Mail Sat, 14 Feb 2026 08
- BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire Fri, 14 Nov 2025 08
- Brainstorm Cell Therapeutics (BCLI) Price Target Decreased by 13.95% to 17.34 - Nasdaq Wed, 29 Oct 2025 07
- Brainstorm Cell raises $1M in private placement at premium pricing - Investing.com Nigeria Fri, 20 Feb 2026 20
- BCLI: Focused on Initiation of Phase 3b ENDURANCE Trial of NurOwn® in ALS… - Yahoo Finance Fri, 15 Aug 2025 07
- Trend Recap: How supply chain issues affect BCLI stock - Trade Signal Summary & Weekly Top Performers Watchlists - mfd.ru Mon, 16 Feb 2026 08
- BrainStorm Cell Therapeutics Crashes After Hours On Nasdaq Delisting Notice; Retail Sees 'Buy Time' - Stocktwits Fri, 18 Jul 2025 07
- BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire hu, 14 Aug 2025 07
- BCLI Stock Price, News & Analysis - Stock Titan hu, 24 Apr 2025 19
- BrainStorm Cell Therapeutics to delist from Nasdaq, move to OTCQB - Investing.com hu, 17 Jul 2025 07
- Nasdaq to delist certain securities suspended from trading (NDAQ:NASDAQ) - Seeking Alpha Wed, 24 Sep 2025 07
- BCLI: Receives Regulatory Clearance to Initiate Phase 3b ALS Trial… - Yahoo Finance ue, 27 May 2025 07
- Brainstorm Cell Therapeutics (BCLI) - Zacks Investment Research Wed, 25 May 2016 00
- BCLI - Brainstorm Cell Therapeutics I Latest Stock News & Market Updates - Stock Titan Mon, 03 Aug 2020 01
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 24000 | — | — | Stock Award(Grant) at price 0.00 per share. | POLVERINO ANTHONY J | Director | — | 2024-12-31 00:00:00 | D |
| 1 | 20000 | — | — | Stock Award(Grant) at price 0.00 per share. | LINDBORG STACY R | Director | — | 2024-12-31 00:00:00 | D |
| 2 | 24000 | — | — | Stock Award(Grant) at price 0.00 per share. | BAIRU MENGHISTEAB M.D. | Director | — | 2024-12-31 00:00:00 | D |
| 3 | 30666 | — | — | Stock Award(Grant) at price 0.00 per share. | NAOR NIR | Director | — | 2024-12-31 00:00:00 | D |
| 4 | 50000 | — | — | Stock Award(Grant) at price 0.00 per share. | DAGHER IBRAHIM B. | Officer | — | 2024-12-31 00:00:00 | D |
| 5 | 40000 | — | — | Stock Award(Grant) at price 0.00 per share. | FRENKEL JACOB A. | Director | — | 2024-12-31 00:00:00 | D |
| 6 | 50000 | — | — | Stock Award(Grant) at price 0.00 per share. | HARTOUNIAN HARTOUN | Chief Operating Officer | — | 2024-12-31 00:00:00 | D |
| 7 | 30666 | — | — | Stock Award(Grant) at price 0.00 per share. | ARBEL IRIT | Director | — | 2024-12-31 00:00:00 | D |
| 8 | 120000 | — | — | Stock Award(Grant) at price 0.00 per share. | LEBOVITS CHAIM | Chief Executive Officer | — | 2024-12-31 00:00:00 | D |
| 9 | 60000 | — | — | Stock Award(Grant) at price 0.00 per share. | YABLONKA URI | Officer and Director | — | 2024-12-31 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -11.60M | -25.87M | -24.54M | -24.28M |
| TotalUnusualItems | 147.00K | 4.69M | ||
| TotalUnusualItemsExcludingGoodwill | 147.00K | 4.69M | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -11.62M | -17.19M | -24.28M | -24.46M |
| ReconciledDepreciation | 240.00K | 265.00K | 285.00K | 260.00K |
| EBITDA | -11.45M | -21.17M | -24.54M | -24.28M |
| EBIT | -11.69M | -21.44M | -24.82M | -24.54M |
| NetInterestIncome | -77.00K | -447.00K | 545.00K | 82.00K |
| InterestIncome | 545.00K | 82.00K | ||
| NormalizedIncome | -11.77M | -21.89M | -24.28M | -24.46M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -11.62M | -17.19M | -24.28M | -24.46M |
| TotalExpenses | 11.69M | 21.44M | 24.82M | 24.54M |
| TotalOperatingIncomeAsReported | -11.69M | -21.44M | -24.82M | -24.54M |
| DilutedAverageShares | 5.02M | 2.87M | 2.43M | 2.41M |
| BasicAverageShares | 5.02M | 2.87M | 2.43M | 2.41M |
| DilutedEPS | -2.31 | -6.00 | -9.90 | -10.20 |
| BasicEPS | -2.31 | -6.00 | -9.90 | -10.20 |
| DilutedNIAvailtoComStockholders | -11.62M | -17.19M | -24.28M | -24.46M |
| NetIncomeCommonStockholders | -11.62M | -17.19M | -24.28M | -24.46M |
| NetIncome | -11.62M | -17.19M | -24.28M | -24.46M |
| NetIncomeIncludingNoncontrollingInterests | -11.62M | -17.19M | -24.28M | -24.46M |
| NetIncomeContinuousOperations | -11.62M | -17.19M | -24.28M | -24.46M |
| PretaxIncome | -11.62M | -17.19M | -24.28M | -24.46M |
| OtherIncomeExpense | 147.00K | 4.69M | ||
| GainOnSaleOfSecurity | 147.00K | 4.69M | ||
| NetNonOperatingInterestIncomeExpense | -77.00K | -447.00K | 545.00K | 82.00K |
| TotalOtherFinanceCost | 77.00K | 447.00K | -545.00K | -82.00K |
| InterestIncomeNonOperating | 545.00K | 82.00K | ||
| OperatingIncome | -11.69M | -21.44M | -24.82M | -24.54M |
| OperatingExpense | 11.69M | 21.44M | 24.82M | 24.54M |
| ResearchAndDevelopment | 4.65M | 10.75M | 13.96M | 15.23M |
| SellingGeneralAndAdministration | 7.04M | 10.69M | 10.87M | 9.30M |
| GeneralAndAdministrativeExpense | 7.04M | 10.69M | 10.87M | 9.30M |
| OtherGandA | 7.04M | 10.69M | 10.87M | 9.30M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 1.67K | 1.67K | 1.67K | 1.67K |
| OrdinarySharesNumber | 6.14M | 4.03M | 2.45M | 2.43M |
| ShareIssued | 6.14M | 4.03M | 2.45M | 2.43M |
| TotalDebt | 720.00K | 1.27M | 4.09M | 5.08M |
| TangibleBookValue | -7.76M | -4.86M | -3.02M | 19.34M |
| InvestedCapital | -7.76M | -4.86M | -3.02M | 19.34M |
| WorkingCapital | -8.59M | -5.90M | -5.69M | 16.96M |
| NetTangibleAssets | -7.76M | -4.86M | -3.02M | 19.34M |
| CapitalLeaseObligations | 720.00K | 1.27M | 4.09M | 5.08M |
| CommonStockEquity | -7.76M | -4.86M | -3.02M | 19.34M |
| TotalCapitalization | -7.76M | -4.86M | -3.02M | 19.34M |
| TotalEquityGrossMinorityInterest | -7.76M | -4.86M | -3.02M | 19.34M |
| StockholdersEquity | -7.76M | -4.86M | -3.02M | 19.34M |
| TreasuryStock | 116.00K | 116.00K | 116.00K | 116.00K |
| RetainedEarnings | -226.64M | -215.01M | -197.82M | -173.54M |
| AdditionalPaidInCapital | 218.97M | 210.26M | 194.91M | 192.99M |
| CapitalStock | 14.00K | 13.00K | 12.00K | 12.00K |
| CommonStock | 14.00K | 13.00K | 12.00K | 12.00K |
| TotalLiabilitiesNetMinorityInterest | 9.60M | 9.07M | 11.47M | 9.94M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 618.00K | 1.27M | 2.67M | 3.62M |
| DerivativeProductLiabilities | 447.00K | 594.00K | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 171.00K | 672.00K | 2.67M | 3.62M |
| LongTermCapitalLeaseObligation | 171.00K | 672.00K | 2.67M | 3.62M |
| CurrentLiabilities | 8.98M | 7.80M | 8.80M | 6.32M |
| CurrentDebtAndCapitalLeaseObligation | 549.00K | 603.00K | 1.43M | 1.46M |
| CurrentCapitalLeaseObligation | 549.00K | 603.00K | 1.43M | 1.46M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.43M | 1.00M | 1.06M | |
| PayablesAndAccruedExpenses | 7.00M | 6.19M | 6.31M | 4.86M |
| CurrentAccruedExpenses | 619.00K | 1.24M | 84.00K | 83.00K |
| Payables | 6.38M | 4.95M | 6.22M | 4.77M |
| DuetoRelatedPartiesCurrent | 300.00K | 0.00 | ||
| AccountsPayable | 6.08M | 4.95M | 6.22M | 4.77M |
| TotalAssets | 1.83M | 4.21M | 8.45M | 29.28M |
| TotalNonCurrentAssets | 1.45M | 2.31M | 5.34M | 6.00M |
| OtherNonCurrentAssets | 206.00K | 207.00K | 23.00K | 27.00K |
| NonCurrentPrepaidAssets | 22.00K | 23.00K | 27.00K | |
| NetPPE | 1.24M | 2.10M | 5.32M | 5.97M |
| AccumulatedDepreciation | -3.00M | -2.76M | -2.50M | -2.21M |
| GrossPPE | 4.24M | 4.87M | 7.82M | 8.18M |
| Leases | 837.00K | 837.00K | 837.00K | 814.00K |
| OtherProperties | 3.08M | 3.70M | 6.66M | 7.05M |
| MachineryFurnitureEquipment | 324.00K | 324.00K | 321.00K | 315.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 385.00K | 1.90M | 3.11M | 23.28M |
| OtherCurrentAssets | 135.00K | 548.00K | 32.00K | 1.10M |
| PrepaidAssets | 1.10M | |||
| Receivables | 63.00K | 51.00K | 91.00K | 86.00K |
| OtherReceivables | 63.00K | 51.00K | 91.00K | 86.00K |
| CashCashEquivalentsAndShortTermInvestments | 187.00K | 1.30M | 2.98M | 22.09M |
| OtherShortTermInvestments | 0.00 | 2.21M | 3.24M | |
| CashAndCashEquivalents | 187.00K | 1.30M | 772.00K | 18.86M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -9.09M | -20.48M | -19.35M | -26.59M |
| RepurchaseOfCapitalStock | 0.00 | |||
| IssuanceOfCapitalStock | 7.97M | 18.98M | 238.00K | 6.96M |
| CapitalExpenditure | -18.00K | -29.00K | -330.00K | |
| EndCashPosition | 371.00K | 1.49M | 772.00K | 18.86M |
| BeginningCashPosition | 1.49M | 772.00K | 18.86M | 37.83M |
| ChangesInCash | -1.11M | 713.00K | -18.08M | -18.97M |
| FinancingCashFlow | 7.97M | 18.98M | 238.00K | 6.97M |
| CashFlowFromContinuingFinancingActivities | 7.97M | 18.98M | 238.00K | 6.97M |
| ProceedsFromStockOptionExercised | 0.00 | 5.00K | ||
| NetCommonStockIssuance | 7.97M | 18.98M | 238.00K | 6.96M |
| CommonStockPayments | 0.00 | |||
| CommonStockIssuance | 7.97M | 18.98M | 238.00K | 6.96M |
| InvestingCashFlow | 12.00K | 2.19M | 998.00K | 323.00K |
| CashFlowFromContinuingInvestingActivities | 12.00K | 2.19M | 998.00K | 323.00K |
| NetInvestmentPurchaseAndSale | 0.00 | 2.21M | 1.03M | 653.00K |
| NetPPEPurchaseAndSale | 12.00K | -18.00K | -29.00K | -330.00K |
| SaleOfPPE | 12.00K | |||
| PurchaseOfPPE | -18.00K | -29.00K | -330.00K | |
| OperatingCashFlow | -9.09M | -20.46M | -19.32M | -26.27M |
| CashFlowFromContinuingOperatingActivities | -9.09M | -20.46M | -19.32M | -26.27M |
| ChangeInWorkingCapital | 1.69M | -496.00K | 2.99M | -3.43M |
| ChangeInOtherCurrentLiabilities | 54.00K | 155.00K | -594.00K | -47.00K |
| ChangeInPayablesAndAccruedExpense | 1.23M | -176.00K | 2.52M | -3.72M |
| ChangeInPayable | 1.23M | -176.00K | 2.52M | -3.72M |
| ChangeInAccountPayable | 1.13M | -1.27M | 2.52M | -1.72M |
| ChangeInPrepaidAssets | 401.00K | -475.00K | ||
| ChangeInReceivables | -475.00K | 1.07M | 335.00K | |
| StockBasedCompensation | 750.00K | 1.49M | 1.68M | 1.37M |
| DepreciationAmortizationDepletion | 240.00K | 265.00K | 285.00K | 260.00K |
| DepreciationAndAmortization | 240.00K | 265.00K | 285.00K | 260.00K |
| Depreciation | 240.00K | 265.00K | 285.00K | 260.00K |
| OperatingGainsLosses | -147.00K | -4.53M | ||
| GainLossOnInvestmentSecurities | -147.00K | -4.53M | ||
| NetIncomeFromContinuingOperations | -11.62M | -17.19M | -24.28M | -24.46M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BCLI
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|